

**GAMROZYNE- gamithromycin injection, solution**  
**Bimeda, Inc**

-----  
**GAMROZYNE™**  
**(gamithromycin)**

**GAMROZYNE™**  
**(gamithromycin)**

**150 mg/mL ANTIMICROBIAL**

For subcutaneous injection in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.


**Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**READ ENTIRE BROCHURE CAREFULLY BEFORE USING THIS PRODUCT**

**DESCRIPTION**

GAMROZYNE Injection for Cattle is a ready to use sterile parenteral solution containing gamithromycin, a macrolide sub-class, 7a-azalide antimicrobial. Each mL of GAMROZYNE contains 150 mg of gamithromycin as the free base, 1 mg of monothioglycerol and 40 mg of succinic acid in a glycerol formal vehicle.

The chemical name of gamithromycin is 1-Oxa-7-azacyclopentadecan-15-one,13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy 3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- $\beta$ -D-xylb-hexopyranosyl]oxy]-, [(2R\*,3S\*,4R\*,5S\*,8R\*,10R\*, 11R\*,12S\*,13S\*,14R\*)]- and the structure is shown below.



**INDICATIONS**

GAMROZYNE is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* in beef and non-lactating dairy cattle. GAMROZYNE is also indicated for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of

developing BRD associated with *Mannheimia haemolytica* and *Pasteurella multocida*.

## **DOSAGE AND ADMINISTRATION**

Administer GAMROZYNE one time as a subcutaneous injection in the neck at 6 mg/kg (2 mL/110 lb) body weight (BW). If the total dose exceeds 10 mL, divide the dose so that no more than 10 mL is administered at each injection site.

<b>Body Weight (lb)</b>	<b>Dose Volume (mL)</b>
110	2
220	4
330	6
440	8
550	10
660	12
770	14
880	16
990	18
1100	20

Animals should be appropriately restrained to achieve the proper route of administration. Use sterile equipment. Inject under the skin in front of the shoulder (see ILLUSTRATION).



## **CONTRAINDICATIONS**

As with all drugs, the use of GAMROZYNE is contraindicated in animals previously found to be hypersensitive to this drug.

### **WARNING:**

**FOR USE IN CATTLE ONLY.**

**NOT FOR USE IN HUMANS.**

**KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.**

**NOT FOR USE IN CHICKENS OR TURKEYS.**

## **CONTACT INFORMATION**

The Safety Data Sheet (SDS) contains more detailed occupational safety information. To report suspected adverse drug events, for technical assistance, or to obtain a copy of the SDS, contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or online at [www.fda.gov/reportanimalae](http://www.fda.gov/reportanimalae)

## **RESIDUE WARNINGS**

Do not treat cattle within 35 days of slaughter. Because a discard time in milk has not been established, do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

## **PRECAUTIONS**

The effects of GAMROZYNE on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection of GAMROZYNE may cause a transient local tissue reaction in some cattle that may result in trim loss of edible tissues at slaughter.

## **ADVERSE REACTIONS**

Transient animal discomfort and mild to moderate injection site swelling may be seen in cattle treated with GAMROZYNE.

## **CLINICAL PHARMACOLOGY**

The macrolide antimicrobials as a class are weak bases and as such concentrate in some cells (such as pulmonary leukocytes). Prolonged exposure of extracellular pulmonary pathogens to macrolides appears to reflect the slow release of drug from its intracellular reservoir to the site of action, the pulmonary epithelial lining fluid (ELF). It is the ELF that is relevant to the successful treatment and control of BRD. Gamithromycin is primarily bacteriostatic at therapeutic concentrations. However, *in vitro* bactericidal activity has been observed at concentrations of 10 µg/mL (Mueller-Hinton broth) and after exposure to the 6-hour and 24-hour plasma samples derived from cattle dosed at 6 mg gamithromycin/kg BW.

Macrolides typically exhibit substantially higher concentrations in the alveolar macrophages and ELF as compared to concentrations observed in plasma. Gamithromycin concentrations in the ELF and ELF cells exceed the concentrations observed in the plasma. Postmortem gamithromycin concentrations in ELF exceed the MIC<sub>90</sub> of *M. haemolytica*, *H. somni* and *P. multocida* through at least 72 hours after drug administration. Because *M. haemolytica*, *P. multocida* and *H. somni* are extracellular pathogens, drug concentrations in the ELF are considered to be clinically relevant. The postmortem area under the concentration-time curve (AUC) observed in lysed ELF cells (e. g., alveolar macrophages) are at least 300-times greater than that in the plasma. Although published studies suggest that inflammation can increase the release of drug from macrophages and neutrophils, these high concentrations in the alveolar macrophages should not be considered indicative of the magnitude or duration of response to the pathogens for which this product is indicated.

Gamithromycin administered subcutaneously in the neck of cattle at a single dosage of 6 mg/kg BW is rapidly and completely absorbed, with peak concentrations generally occurring within 1 hour after administration. Based upon plasma and lung homogenate data, the terminal half-life (T<sub>1/2</sub>) of gamithromycin is approximately 3 days. *In vitro* plasma protein binding studies show that 26% of the gamithromycin binds to plasma protein, resulting in free drug available for rapid and extensive distribution into body tissues. The free drug is rapidly cleared from the systemic circulation with a clearance rate of 712 mL/hr/kg and a volume of distribution of 25 L/kg. Dose proportionality was established based on AUC over a range of 3 mg/kg BW to 9 mg/kg BW. Biliary excretion of the unchanged drug is the major route of elimination.

## **MICROBIOLOGY**

The minimum inhibitory concentrations (MIC's) of gamithromycin were determined for BRD isolates obtained from calves enrolled in BRD treatment field studies in the U.S. in 2004 using methods recommended by the Clinical and Laboratory Standards Institute (M31-A2). Isolates were obtained from pre-treatment nasopharyngeal swabs from each enrolled calf and from calves removed from the study due to BRD. The results are shown below in Table 1.

<b>Table 1. Gamithromycin minimum inhibitory concentration (MIC) values* of indicated pathogens isolated from BRD treatment field studies in the U.S.</b>					
<b>Indicated Pathogens</b>	<b>Years of Isolation</b>	<b>No. of isolates</b>	<b>MIC<sub>50</sub>† (µg/mL)</b>	<b>MIC<sub>90</sub>† (µg/mL)</b>	<b>MIC range (µg/mL)</b>
<i>M. haemolytica</i>	2004	89	1	1	0.5 to >32
<i>P. multocida</i>	2004	79	0.5	1	0.12 to >32
<i>H. somni</i>	2004	32	0.5	0.5	0.25 to 1

\* The correlation between *in vitro* susceptibility data and clinical effectiveness is unknown.

† The lowest MIC to encompass 50% and 90% of the most susceptible isolates, respectively.

## EFFECTIVENESS

The effectiveness of gamithromycin for the treatment of BRD associated with *Mannheimia haemolytica*, *Pasteurella multocida* and *Histophilus somni* was demonstrated in a field study conducted at four geographic locations in the United States. A total of 497 cattle exhibiting clinical signs of BRD were enrolled in the study. Cattle were administered gamithromycin (6 mg/kg BW) or an equivalent volume of sterile saline as a subcutaneous injection once on Day 0. Cattle were observed daily for clinical signs of BRD and were evaluated for clinical success on Day 10. The percentage of successes in cattle treated with gamithromycin (58%) was statistically significantly higher ( $p < 0.05$ ) than the percentage of successes in the cattle treated with saline (19%).

The effectiveness of gamithromycin for the treatment of BRD associated with *M. bovis* was demonstrated independently at two U.S. study sites. A total of 502 cattle exhibiting clinical signs of BRD were enrolled in the studies. Cattle were administered gamithromycin (6 mg/kg BW) or an equivalent volume of sterile saline as a subcutaneous injection once on Day 0. At each site, the percentage of successes in cattle treated with gamithromycin on Day 10 was statistically significantly higher than the percentage of successes in the cattle treated with saline (74.4% vs. 24% [ $p < 0.001$ ], and 67.4% vs. 46.2% [ $p = 0.002$ ]). In addition, in the group of calves treated with gamithromycin that were confirmed positive for *M. bovis* (pre-treatment nasopharyngeal swabs), there were more calves at each site (45 of 57 calves, and 5 of 6 calves) classified as successes than as failures.

The effectiveness of gamithromycin for the control of respiratory disease in cattle at high risk of developing BRD associated with *Mannheimia haemolytica* and *Pasteurella multocida* was demonstrated in two independent studies conducted in the United States. A total of 467 crossbred beef cattle at high risk of developing BRD were enrolled in the study. Gamithromycin (6 mg/kg BW) or an equivalent volume of sterile saline was administered as a single subcutaneous injection within one day after arrival. Cattle were observed daily for clinical signs of BRD and were evaluated for clinical success on Day 10 post-treatment. In each of the two studies, the percentage of successes in the cattle treated with gamithromycin (86% and 78%) was statistically significantly higher ( $p =$

0.0019 and  $p = 0.0016$ ) than the percentage of successes in the cattle treated with saline (36% and 58%).

## **ANIMAL SAFETY**

In a target animal safety study in healthy, six-month old beef cattle, gamithromycin was administered by subcutaneous injection at 6, 18, and 30 mg/kg bodyweight (1, 3, and 5 times the labeled dose) on Day 0, 5, and 10 (3 times the labeled administration frequency). Injection site discomfort (neck twisting, attempts to scratch or lick the injection site, and pawing at the ground) was observed in calves in the 18 mg/kg BW and 30 mg/kg BW groups at 10 minutes post-treatment following each injection. Mild to moderate injection site swelling and pathology changes consistent with inflammation were observed in the gamithromycin-treated groups. Other than injection site reactions, no clinically relevant treatment-related effects were observed.

## **STORAGE CONDITIONS**

Store at or below 77°F (25°C) with excursions between 59-86°F (15-30°C). Use within 28 days of first puncture. If using multi-dosing equipment with a draw-off spike 4 gauge or smaller, puncture a maximum of 5 times. When using a needle larger than 16 gauge, or a draw-off spike larger than 4 gauge, discard any remaining product immediately after use.

## **HOW SUPPLIED**

GAMROZYNE is available in three ready-to-use bottle sizes. The 100, 250 and 500 mL bottles contain sufficient solution that will treat 10, 25 and 50 head of 550 lb (250 kg) cattle respectively.

Approved by FDA under ANADA # 200-819

GAMROZYNE is a trademark of Bimeda, Inc.

### **Manufactured for:**

Bimeda, Inc.

Le Sueur, MN 56058

Made in Canada

05/25

See package insert for complete product information.


Each mL of GAMROZYNE contains 150 mg of gamithromycin as the free base, 1 mg of monothioglycerol and 40 mg of succinic acid in a glycerol formal vehicle.

**INDICATIONS:** GAMROZYNE is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* in beef and non-lactating dairy cattle. GAMROZYNE is also indicated for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with *Mannheimia haemolytica* and *Pasteurella multocida*.

**DOSAGE AND ADMINISTRATION:**  
Administer GAMROZYNE one time as a subcutaneous injection in the neck at 6 mg/kg (2 mL/110 lb) body weight (BW). If the total dose exceeds 10 mL, divide the dose so that no more than 10 mL is administered at each injection site.

**WARNING: FOR USE IN CATTLE ONLY. NOT FOR USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN. NOT FOR USE IN CHICKENS OR TURKEYS.**

NDC: 61133-4015-3




**150 mg/mL**

**Antimicrobial**


For subcutaneous injection in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Approved by FDA under ANADA # 200-819



500 mL



**CONTACT INFORMATION:** The Safety Data Sheet (SDS) contains more detailed occupational safety information. To report suspected adverse drug events, for technical assistance, or to obtain a copy of the SDS, contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or online at [www.fda.gov/reportanimalae](http://www.fda.gov/reportanimalae)

**RESIDUE WARNINGS:** Do not treat cattle within 35 days of slaughter. Because a discard time in milk has not been established, do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

**STORAGE CONDITIONS:** Store at or below 77°F (25°C) with excursions between 59-86°F (15-30°C). Use within 28 days of first puncture. If using multi-dosing equipment with a draw-off spike 4 gauge or smaller, puncture a maximum of 5 times. When using a needle larger than 16 gauge, or a draw-off spike larger than 4 gauge, discard any remaining product immediately after use.

**Manufactured for:**  
Bimeda, Inc.  
Le Sueur, MN 56058  
[www.bimeda.com](http://www.bimeda.com)  
Made in Canada

PULL

GAMROZYNE is a trademark of Bimeda, Inc.  
 t GAM003 85AM003 Rev 05/25

## GAMROZYNE

gamithromycin injection, solution

### Product Information

<b>Product Type</b>	PRESCRIPTION ANIMAL DRUG	<b>Item Code (Source)</b>	NDC:61133-4015
<b>Route of Administration</b>	SUBCUTANEOUS		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>GAMITHROMYCIN</b> (UNII: ZE856183S0) (GAMITHROMYCIN - UNII:ZE856183S0)	GAMITHROMYCIN	150 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
<b>MONOTHIOGLYCEROL</b> (UNII: AA01P0WSXJ)	1 mg in 1 mL
<b>SUCCINIC ACID</b> (UNII: AB6MNQ6J6L)	40 mg in 1 mL
<b>GLYCEROL FORMAL</b> (UNII: 3L7GR2604E)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:61133-4015-1	100 mL in 1 BOTTLE, GLASS		
2	NDC:61133-4015-2	250 mL in 1 BOTTLE, GLASS		
3	NDC:61133-4015-3	500 mL in 1 BOTTLE, GLASS		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200819	10/01/2025	

**Labeler -** Bimeda, Inc (060492923)

## Establishment

Name	Address	ID/FEI	Business Operations
Bimeda- MTC		256232216	manufacture

Revised: 9/2025

Bimeda, Inc